The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
Open accessAbstract
SUMMARY Protein glycosylation provides proteomic diversity in regulating protein localization, stability and activity; it remains largely unknown whether the sugar moiety contributes to immunosuppression. In the study of immune receptor glycosylation, we showed EGF induces PD-L1 and receptor programmed cell death protein-1 (PD-1) interaction, requiring β-1,3-N-acetylglucosaminyl transferase (B3GNT3) expression in triple-negative breast cancer. Downregulation of B3GNT3 enhances cytotoxic T cell-mediated anti-tumor immunity. A monoclonal antibody targeting glycosylated PD-L1 (gPD-L1) blocks PD-L1/PD-1 interaction and promotes PD-L1 internalization and degradation. In addition to immune reactivation, drug-conjugated gPD-L1 antibody induces potent cell-killing effect as well as bystander-killing effect on adjacent cancer cells lacking PD-L1 expression without any detectable toxicity. Our work suggests targeting protein glycosylation as a potential strategy to enhance immune checkpoint therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · cited 1×
“…interaction with PD-1 and subs sylation-specific antibody that can efficiently internalize PD-L1 against glycosylated PD-L1, which induces potent anti-tumor open a direction to target glycosylation of co-inhibitory ligand Cancer and cytolytic activity (Dong et al., 2002; Krummel and Allison, 1995).”
BackgroundInhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
Chen, L., & Han, X. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80011 · Cited by 1,437
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,382
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314
Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Li, C.-W., Lim, S.-O., Xia, W., Lee, H.-H., Chan, L.-C., Kuo, C.-W., Khoo, K.-H., Chang, S.-S., Cha, J.-H., Kim, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms12632 · Cited by 1,091
Self-citationQuantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
McLaughlin, J., Han, G., Schalper, K. A., Carvajal-Hausdorf, D., Pelekanou, V., Rehman, J., Velcheti, V., Herbst, R., LoRusso, P., & Rimm, D. L. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.3638 · Cited by 837
Deubiquitination and Stabilization of PD-L1 by CSN5
Lim, S.-O., Li, C.-W., Xia, W., Cha, J.-H., Chan, L.-C., Wu, Y., Chang, S.-S., Lin, W.-C., Hsu, J.-M., Hsu, Y.-H., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.010 · Cited by 793
Self-citationDirix, L. Y., Takacs, I., Jerusalem, G., Nikolinakos, P., Arkenau, H.-T., Forero-Torres, A., Boccia, R., Lippman, M. E., Somer, R., Smakal, M., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4537-5 · Cited by 746
Glycosidase inhibitors: update and perspectives on practical use
Asano, N. (2003) · Glycobiology · doi:10.1093/glycob/cwg090 · Cited by 715
Mechanisms and principles of N-linked protein glycosylation
Schwarz, F., & Aebi, M. (2011) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2011.08.005 · Cited by 695
Liu, J., Hamrouni, A., Wolowiec, D., Coiteux, V., Kuliczkowski, K., Hetuin, D., Saudemont, A., & Quesnel, B. (2007) · Blood · doi:10.1182/blood-2006-10-051482 · Cited by 580
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Response
Sznol, M., & Chen, L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2234 · Cited by 528
Croci, D. O., Cerliani, J. P., Dalotto-Moreno, T., Méndez-Huergo, S. P., Mascanfroni, I. D., Dergan-Dylon, S., Toscano, M. A., Caramelo, J. J., García-Vallejo, J. J., Ouyang, J., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.043 · Cited by 505
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
Sznol, M., & Chen, L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2063 · Cited by 488
Li, C.-W., Xia, W., Huo, L., Lim, S.-O., Wu, Y., Hsu, J. L., Chao, C.-H., Yamaguchi, H., Yang, N.-K., Ding, Q., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3123 · Cited by 467
Self-citationPrecision glycocalyx editing as a strategy for cancer immunotherapy
Xiao, H., Woods, E. C., Vukojicic, P., & Bertozzi, C. R. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608069113 · Cited by 440
Li, J. Y., Perry, S. R., Muniz-Medina, V., Wang, X., Wetzel, L. K., Rebelatto, M. C., Hinrichs, M. J. M., Bezabeh, B. Z., Fleming, R. L., Dimasi, N., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.008 · Cited by 397
Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
Okeley, N. M., Miyamoto, J. B., Zhang, X., Sanderson, R. J., Benjamin, D. R., Sievers, E. L., Senter, P. D., & Alley, S. C. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2069 · Cited by 393
Yeh, J.-C., Hiraoka, N., Petryniak, B., Nakayama, J., Ellies, L. G., Rabuka, D., Hindsgaul, O., Marth, J. D., Lowe, J. B., & Fukuda, M. (2001) · Cell · doi:10.1016/s0092-8674(01)00394-4 · Cited by 346
Galectin–glycan lattices regulate cell-surface glycoprotein organization and signalling
Garner, O. B., & Baum, L. G. (2008) · Biochemical Society Transactions · doi:10.1042/bst0361472 · Cited by 226
Clathrin-mediated Endocytosis of MUC1 Is Modulated by Its Glycosylation State
Altschuler, Y., Kinlough, C. L., Poland, P. A., Bruns, J. B., Apodaca, G., Weisz, O. A., & Hughey, R. P. (2000) · Molecular Biology of the Cell · doi:10.1091/mbc.11.3.819 · Cited by 190
Antibody drug conjugates: lessons from 20 years of clinical experience
Tolcher, A. W. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw424 · Cited by 165
Shiraishi, N., Natsume, A., Togayachi, A., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m004800200 · Cited by 142
Adams, S., Schmid, P., Rugo, H. S., Winer, E. P., Loirat, D., Awada, A. H., Cescon, D. W., Iwata, H., Campone, M., Nanda, R., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.1008 · Cited by 132
Schmid, P., Cruz, C., Braiteh, F. S., Eder, J. P., Tolaney, S. M., Kuter, I., Nanda, R., Chung, C. T., Cassier, P. A., Delord, J., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-2986 · Cited by 119
Dirix, L. Y., Takács, I., Nikolinakos, P. G., Jérusalem, G., Arkenau, H., Hamilton, E. P., von Heydebreck, A., Grote, H.-J., Chin, K. M., & Lippman, M. (2016) · Cancer Research · doi:10.1158/1538-7445.sabcs15-s1-04 · Cited by 112
Hennet, T., Dinter, A., Kuhnert, P., Mattu, T. S., Rudd, P. M., & Berger, E. G. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.1.58 · Cited by 102
Perillo, E. P., Liu, Y., Huynh, K. T., Liu, C., Chou, C., Hung, M., Yeh, H., & Dunn, A. K. (2015) · Nature Communications · doi:10.1038/ncomms8874 · Cited by 88
Self-citationEnhanced receptor–clathrin interactions induced by N -glycan–mediated membrane micropatterning
Torreno-Pina, J. A., Castro, B. M., Manzo, C., Buschow, S. I., Cambi, A., & Parajo, M. F. G. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402041111 · Cited by 72
Functional consequences of alteration of N-linked glycosylation sites on the neurokinin 1 receptor
Tansky, M. F., Pothoulakis, C., & Leeman, S. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703394104 · Cited by 64
Scanning N-glycosylation mutagenesis of membrane proteins
Cheung, J. C., & Reithmeier, R. A. F. (2007) · Methods · doi:10.1016/j.ymeth.2006.10.002 · Cited by 49
Sugahara, D., Kaji, H., Sugihara, K., Asano, M., & Narimatsu, H. (2012) · Scientific Reports · doi:10.1038/srep00680 · Cited by 23
Kamei, N., Fukui, R., Suzuki, Y., Kajihara, Y., Kinoshita, M., Kakehi, K., Hojo, H., Tezuka, K., & Tsuji, T. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.11.098 · Cited by 16
Cited by
Regulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Jiang, X., Wang, J., Deng, X., Xiong, F., Ge, J., Xiang, B., Wu, X., Ma, J., Zhou, M., Li, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-018-0928-4 · Cited by 1,457
Immune checkpoint signaling and cancer immunotherapy
He, X., & Xu, C. (2020) · Cell Research · doi:10.1038/s41422-020-0343-4 · Cited by 1,371
Mechanisms Controlling PD-L1 Expression in Cancer
Cha, J.-H., Chan, L.-C., Li, C.-W., Hsu, J. L., & Hung, M.-C. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.09.030 · Cited by 1,045
Self-citationAutophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy
Gao, W., Wang, X., Zhou, Y., Wang, X., & Yu, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01046-3 · Cited by 1,042
Metadata
- Authors
- Li, C.-W., Lim, S.-O., Chung, E. M., Kim, Y.-S., Park, A. H., Yao, J., Cha, J.-H., Xia, W., Chan, L.-C., Kim, T., Chang, S.-S., Lee, H.-H., Chou, C.-K., Liu, Y.-L., Yeh, H.-C., Perillo, E. P., Dunn, A. K., Kuo, C.-W., Khoo, K.-H., Hsu, J. L., Wu, Y., Hsu, J.-M., Yamaguchi, H., Huang, T.-H., Sahin, A. A., Hortobagyi, G. N., Yoo, S. S., & Hung, M.-C.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 33
- Issue
- 2
- Pages
- 187-201.e10
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2787095966
- Cited by
- 602
- References
- 43
- FWCI
- 18.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.